BAVENCIO® (avelumab) Mechanism of Action

You are about to leave this site and are being redirected to another site. Would you like to leave this site?

Not all PD-1/PD-L1 inhibitors are the same

BAVENCIO® (avelumab) is the first and only FDA-approved human anti-PD-L1 immunotherapy with dual engagement of both the adaptive and innate immune systems


Click to view

Preclinical and in vitro data may not necessarily correlate with clinical outcomes.

Adaptive immune response

BAVENCIO has been shown to release the suppression of the T cell-mediated antitumor immune response by blocking the interaction of PD-L1 with PD-1 receptors in preclinical models1-3

Innate immune response

BAVENCIO has also been shown to induce NK
cell-mediated direct tumor cell lysis via antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro3-5

References: 1. Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control. 2014;21(3):231-237. 2. Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV. FcyRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell. 2015;28(3):285-295. 3. Hamilton G, Rath B. Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opin Biol Ther. 2017;17(4):515-523. 4. Kohrt HE, Houot R, Marabelle A, et al. Combination strategies to enhance antitumor ADCC. Immunotherapy. 2012;4(5):511-527. 5. Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res. 2015;3(10):1148-1157.